Genmark Diagnostics Inc (NASDAQ:GNMK)
| 14.77 Data as of May 24 |  +0.11 / +0.75%Today’s Change | 4.01 Today|||52-Week Range 16.00 | +64.11% Year-to-Date |
Latest GNMK News | Press Releases
No recent news for Genmark Diagnostics Inc.
Today’s Trading
| Previous close | 14.66 |
| Today’s open | 14.56 |
| Day’s range | 14.32 - 14.84 |
| Volume | 40,785 |
| Average volume (3 months) | 159,166 |
| Market cap | $480.4M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/24/2013
Growth & Valuation
| Earnings growth (last year) | +42.07% |
| Earnings growth (this year) | +5.75% |
| Earnings growth (next 5 years) | +30.00% |
| Revenue growth (last year) | +308.64% |
| P/E ratio | NM |
| Price/Sales | 11.53 |
| Price/Book | 8.51 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| EXAMExamWorks Group Inc | +0.18 | +0.98% |
| CCMConcord Medical Serv... | -0.04 | -0.96% |
| CTICCell Therapeutics In... | +0.02 | +1.64% |
| NBSNeoStem Inc | +0.02 | +3.51% |
Data as of 4:04pm ET, 05/24/2013
Financials
| Next reporting date | August 6, 2013 |
| EPS forecast (this quarter) | -$0.23 |
| Annual revenue (last year) | $20.5M |
| Annual profit (last year) | -$22.1M |
| Net profit margin | -107.98% |
Profile
Sector Health Technology |
Industry Medical Specialties |
Chairman Christopher M. Gleeson |
Chief Scientific Officer Jon Faiz Kayyem, PhD |
Corporate headquarters Carlsbad, California |
Forecasts
